Towards improved therapies using nanopharmaceuticals: Recent patents on pharmaceutical nanoformulations

Recent Patents on Food, Nutrition and Agriculture

Volumn 4, Issue 3, 2012, Pages 220-244

  Horstkotte, Elke ^a   Odoerfer, Kathrin I ^a  

^a Leon Nanodrugs GmbH   (Germany)

Author keywords

Dissolution rate; Nanoformulations; Nanopharmaceuticals; Oral bioavailability; Solubility

Indexed keywords

DRUG; NANOPARTICLE;

ARTICLE; CHEMISTRY; HUMAN; NANOMEDICINE; PATENT;

CHEMISTRY, PHARMACEUTICAL; HUMANS; NANOMEDICINE; NANOPARTICLES; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS;

EID: 84870407350     PISSN: 22127984     EISSN: 18761429     Source Type: Journal    
DOI: 10.2174/2212798411204030220     Document Type: Article

References (90)

1. Vishwanathan R, Wilson T, Nicolosi RJ. Bioavailability of a nanoemulsion of Lutein is greater than a Lutein supplement. Nano Biomed Eng 2009;1:38-49.
2. Boisseau P, Loubaton B. Nanomedicine, nanotechnology in medicine. C R Physique 2011;12:620-36.
3. European Science Foundation. Nanomedicine: An ESF-European Medical Research Councils Forward Look report, 2005. Available at: http://www.esf.org. (Accessed on August 10, 2012).
4. Scott NR. Nanotechnology and animal health. Rev Sci Tech Off Int Epiz 2005;24:425-32. (Pubitemid 41112558)
5. Manuja A, Kumar B, Singh RK. Nanotechnology developments: opportunities for animal health and production. Nanotech Dev 2012;2:17-25.
6. Dunzeweiler N, Wagner V. Nanotechnology in Medicine: New Perspectives for the Life Sciences Industry, Ernst & Young AG: 2008.
7. Pohl-Apel G. Mit Nanopartikeln Wirkstoffe ans Ziel bringen. Biospektrum 2010;16:816-817.
8. Dang Y, Zhang Y, Fan L, Chen H, Roco MC. Trends in worldwide nanotechnology patent applications: 1991 to 2008. J Nanopart Res 2010;12:687-706.
9. Moghimi SM, Hunte AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005;19:311-30. (Pubitemid 40316520)
10. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008;4:273-82.
11. Jain KK. Nanomedicine: Application of nanobiotechnology in medical practice. Med Princ Pract 2008;17:89-101. (Pubitemid 351301293)
12. Seigneuric R, Markey L, Nuyten DS, Dubernet C, Evelo CT, Finot E, et al. From nanotechnology to nanomedicine: Applications to cancer research. Curr Mol Med 2010;10:640-52.
13. Conde J, Doria G, Baptista P. Noble metal nanoparticles applications in cancer. J Drug Deliv 2012, article ID 751075:12 pages.
14. Gupta RB, Kompella UB. Nanoparticle Technology for Drug Delivery. Taylor & Francis: New York: 2006:4-5.
15. Roduner E. Size matters: why nanomaterials are different. Chem Soc Rev 2006;35:583-92. (Pubitemid 43948237)
16. Lipinski C. Poor aqueous solubility - an industry wide problem in drug discovery. Am Pharm Rev 2002;5:82-5.
17. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007;59:603-16. (Pubitemid 47285406)
18. Savolainen J, Järvinen K, Taipale H, Jarho P, Loftsson T, Järvinen T. Co-Administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm Res 1998;15:1696-701. (Pubitemid 28524579)
19. Ruddy SB, Matuszewska BK, Grim, YA, Ostovic D, Storey DE. Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. Int J Pharm 1999;182:173-86. (Pubitemid 29248846)
20. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068-75. (Pubitemid 350186132)
21. Douroumis D, Fahr A. Nano-And micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique. Eur J Pharm Biopharm 2006;63:173-75. (Pubitemid 43776205)
22. Lee BS, Kang MJ, Choi WS, Choi YB, Kim HS, Lee SK et al. Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. Arch Pharm Res 2009;32:1629-35.
23. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008;36:43-8.
24. Amidon GJ, Lennernäs H, Shap VP, Crison JR. A theoretical basis for a bio-pharmaceutic drug classification: The correlation of in vitro drug product dis-solution and in vivo bioavailability. Pharm Res 1995;12:413-20.
25. Bosch, W. H., Merisko-Liversidge, E. M., Shelukar, S., Thompson, K. C. Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist. WO2003049718 (2002).
26. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 2004;285:135-46. (Pubitemid 39361543)
27. Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. Predicting pharmacokinetics of drugs using physiologically based modeling-Application to food effects. AAPS J 2009;1:45-53.
28. Filipcsei, G., Ötvös, Z., Heltovics, G., Darvas, F. Nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. WO2011158053 (2011).
29. Stamm, A., Seth, P. Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it. US6277405 (2001).
30. Ryde, N. P., Ruddy, S. B. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate. US6375986 (2002).
31. Stamm, A., Seth, P. Fenofibrate pharmaceutical composition having high bioavailability. US6652881 (2003).
32. Stamm, A., Seth, P. Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it. US7037529 (2006).
33. Stamm, A., Seth, P. Fenofibrate pharmaceutical composition having high bioavailabilty. US7041319. (2006).
34. Ryde, R., Gustow, E. E., Ruddy, S. B., Jain, R., Patel, R., Wilkins, M. J. Nanoparticulate fibrate formulations. US7276249 (2005).
35. Ryde, R., Gustow, E. E., Ruddy, S. B., Jain, R., Patel, R., Wilkins, M. J. Nanoparticulate fibrate formulations. US7320802 (2004).
36. Holm, P., Norling, T. Solid dosage form comprising a fibrate. US7658944. (2005).
37. Holm, P., Norling, T. Solid dosage form comprising a fibrate. US8124125. (2010).
38. Arnold, K. A., Feng, H. Methods of use of fenofibric acid. US7569612 (2008).
39. Arnold, K. A., Feng, H. Methods of use of fenofibric acid. US7741373 (2009).
40. Arnold, K. A., Feng, H. Methods of use of fenofibric acid. US7741374 (2009).
41. Arnold, K. A., Feng, H. Methods of use of fenofibric acid. US7915247 (2008).
42. Sessa G, Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. Journal of lipid research 1968;9(3):310-8.
43. Chrastina A, Massey KA, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:421-37.
44. Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: A powerful and flexible strategy to improve the drug delivery. Cur Drug Metab 2012;13:105-19.
45. Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995, 16:215-233.
46. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 2008;5:371-383. (Pubitemid 351721718)
47. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-1458. (Pubitemid 41483874)
48. Hirsjärvi S, Passirani C, Benoit J-P. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol 2011;8:188-96.
49. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9. (Pubitemid 38444547)
50. Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): A new approach in breast cancer therapy. Expert Opin Pharmacother 2002;3:1739-51. (Pubitemid 36054595)
51. Ishida T, Kashima S, Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. Journal Control Release. 2008;126:162-5.
52. Schipper ML, Cheng Z, Lee SW, Bentolila LA, Iyer G, Rao J et al. microPET-based biodistribution of quantum dots in living mice. J Nucl Med 2007;48:1511-1518. (Pubitemid 47397401)
53. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, et al. Antibody against poly (ethylene glycol) adversely affects PEG-Asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110:103-11. (Pubitemid 46986423)
54. Sarris, A. H., Cabanillas, F., Logan, P. M., Burge, C. T. R., Goldie, J. H., Webb, M. S. Compositions and methods for treating lymphoma. US7887836 (2008).
55. ® (vincristine sulfate liposomes injection) for the treatment of advanced relapsed and/or refractory philadelphia chromosome negative (ph-) adult acute lymphoblastic leukemia (2012). http://www.fda.gov/ downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM296424.pdf (Accessed on: June 23, 2012)
56. Bennett CL, Adegboro OS, Calhoun EA, Raisch D. Beyond the black box: drug-And device-Associated hypersensitivity events. Drug Healthc Patient Saf 2010;2:1-5.
57. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai NP, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803. (Pubitemid 46657376)
58. Desai NP, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24. (Pubitemid 43342524)
59. U. S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: http://www.accessdata. fda.gov/scripts/cder/ob/docs/patexclnew.cf m?Appl-No=021660&Product-No= 001&table1=OB-Rx (Accessed on: June 23, 2012)
60. Prendergast WF, Schafer HN. Nanocrystalline Pharmaceutical Patent Litigation: The First Case. Nanotechnology Law & Business 2008;438(06):157-162.
61. Liversidge, G. G., Liversidge, E., Sarpotdar, P. P. Surface modified anticancer nanoparticles. US5399363 (1992).
62. de Garavilla, L., Liversidge, E., Liversidge, G. G. Reduction of intravenously administered nanoparticulate formulation-induced adverse physiological reactions. US5834025 (1996).
63. Dang Y, Zhang Y, Fan L, Chen H, Roco M C. Trends in worldwide nanotechnology patent applications: 1991 to 2008. J Nanopart Res 2010;12:687-706.
64. European Patent Office: Available at: http://www.epo.org/newsissues/ issues/classification/nanotechnology-de.html (Accessed on: June 23, 2012)
65. World Intellectual Property Organisation. Available at: http://www.wipo.int/patentscope/search/en/search.jsf (Accessed on: June 23, 2012)
66. Barenholz, Y. Doxil - The First FDA-Approved Nano-Drug: From an Idea to a Product. in: Handbook of Harnessing Biomaterials in Nanomedicine 0, 978-981 (2012).
67. Martin, F. J. Case Study: DOXIL, the Development of Pegylated Liposomal Doxorubicin. Injectable Dispersed Systems 20053164, (2005).
68. Barenholz, Y., Haran, G. Method of amphiphatic drug loading in liposomes by pH gradient. US5192549 (1993).
69. Barenholz, Y., Haran, G. Method of amphiphatic drug loading in liposomes by ammonium ion gradient. US5316771 (1994).
70. Woodle, M. C., Martin, F. J., Yau-Young, A., Redemann, C. T. Liposomes with enhanced circulation time. US5013556 (1991).
71. Chang H-I, Yeh M K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012;7:49-60.
72. Liversidge, G. G., Cundy, K. C., Bishop, J. F., Czekai, D. A. Surface modified drug nanoparticles. US5145684 (1991).
73. Lee RW, McShane J, Shaw JM, Wood RW, Shenoy DB. Particle size reduction. water-insoluble drug formulation. CRC Press 2008; Chapter 17.)
74. Lee RW. Development and Scale-Up of NanoCrystal Particles. Injectable Dispersed Systems. Informa Healthcare 2005:355-70.
75. Gaulin, A. Procédé et appareil perfectionné pour fixer la composition du lait. FR323875 (1903).
76. Möschwitzer, Bushrab, Müller. Manufacturing of Nanoparticles by Milling and Homogenization Techniques. Nanoparticle Technology for Drug Delivery, Editors Gupta, Kompella Informa Healthcare 2006: Chapter 2.
77. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. US5858410. (1999).
78. Snow RH, Allen T, Ennis BJ, Litster J. Size Reduction and Size Enlargement. In: Perry's Chemical Engineers Handbook. 1997.
79. Müller RH, Jacobs C, Kayser O. DissoCubes: Novel Formulation for Poorly Soluble and Poorly Bioavailable Drugs. Rathbone M, Hadgraft J, Roberts M. Modified-Release Drug Delivery Technology. Informa Healthcare 2002:135-49.
80. Müller, R. H., Krause, K., Mader, K. Method for controlled production of ultrafine microparticles and nanoparticles. WO2001003670 (2001).
81. Panagiotou T, Mesite SV, Bernard JM, Chomistek KJ, Fisher RJ. Production of Polymer Nanosuspensions Using Microfluidizer Processor Based Technologies. NSTI-Nanotech 2008;1:688-91.
82. Panagiotou T, Mesite SV, Fisher RJ. Production of Norfloxacin Nanosuspensions Using Microfluidics Reaction Technology through Solvent/Antisolvent Crystallization. I&EC Research 2009;48:1761-71.
83. Microfluidics. Available at: http://www.microfluidicscorp.com/ (Accessed on: June 23, 2012)
84. Bruno RP, Mcilwrick R. Microfluidizer processor technology for high performance particle size reduction, mixing and dispersion. Dispersion techniques for laboratory and industrial scale processing. Wissenschaftliche Verlagsgesellschaft Stuttgart 2001:77-89.
85. Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008;3:295-309.
86. ™ as Platform Brand Name of MRT Technology Applications, 27-01-2011
87. United States Patent and Trademark Office. Assignment Database. Search Term "Assignee Name = MICROFLUIDICS", Available at: http://assignments.uspto.gov/assignments/q?db=pat (Accessed on: June 23, 2012)
88. Nangenex. Available at: http://www.nangenex.com/en/technology/ (Accessed on: June 23, 2012)
89. Niesz, K., Wootsch, A., Groualle, M., Ötvös, Z., & Darvas, F. Instrument and Process for Nanoparticles Production in continuous flow mode. WO2009133418 (2009).
90. Nangenex. Available at: http://nangenex.com/en/new&publications/ (Accessed on: June 23, 2012)